Featured
Read our handpicked blogs, curated for you.
|
For Indian pharma, HCP engagement is no longer about reach; it’s about relevance and measurable impact. Boards want to…
|
Pharma marketing in India is at a turning point. Budgets have expanded, channels have multiplied, and compliance…
|
If you’re serious about HCP Engagement Tier 2 Cities, stop chasing metro playbooks. Tier 2 doctors don’t sit in front…
Recent releases
|
Why Personalization in Pharma is Not Optional Anymore
Pharma has reached a turning point. Doctors don’t want generic detailers sent in bulk. Patients don’t trust one-size-fits-all education campaigns. Regulators demand accuracy, and competitors are…
|
Schedule H, MLR Reviews, and Tech: Making Compliance Invisible
Compliance is the make-or-break factor in pharma marketing; creativity means nothing if compliance collapses. Every CMO in India knows this. Schedule H drugs come with strict guidelines. UCPMP 2024…
|
Why Field Force Enablement Needs to Be MarTech’s Next Frontier
Here's the overlooked truth: in Indian pharma boardrooms, digital transformation usually gets framed around CRM platforms, doctor engagement dashboards, or omnichannel campaigns. But let’s be…
|
10 MarTech for Pharma Metrics That Actually Matter in Pharma Marketing in 2025
Moving past vanity metricsPharma CMOs in India have had enough of dashboards cluttered with “likes,” “clicks,” and “reach.” Those numbers look good in quarterly reviews, but they don’t answer the…
